Novel stem cell treatment to combat pediatric inflammatory response during cardiopulmonary bypass surgery

Abstract Cardioplegia and exposure to the heart-lung machine required in cardiopulmonary bypass induce a systemic inflammatory response. Adverse effects cause longer ICU stays, higher medical costs, worsened mortality morbidity, especially neonatal pediatric populations. nCPCs have been shown regenerative anti-inflammatory properties when introduced animal studies as treatment. Surgeons at UMB performed surgery on non survival porcine subjects with control treatment group of 6 each. NDMU tested analyzed serum samples for immunological markers or interleukins. The results revealed that does seem an effect pro-inflammatory cytokines TNF-α, IL-1β, IL-6. IL-6 concentrations decreased significantly from 3124 1480 pg/mL, 8319 2714 18,011 10,825 respectively. Furthermore, also has IL-10, cytokine, noted by increase 289 328 mg/mL. Overall, seems greater macrophage immune response, while it little no neutrophil are currently working subjects. Moreover, H&E staining RT-qPCR will be determine localization damage relative expression interest.